Skip to main content
. 2017 Jul 25;7:6457. doi: 10.1038/s41598-017-06451-1

Figure 3.

Figure 3

ORAI1 and STIM1 protein abundance in neurons generated from healthy volunteers and from ChAc patients without or with lithium treatment without and with SGK1 inhibitor GSK650394. (a) Original Western blot of ORAI1 protein abundance in neurons differentiated from healthy volunteers (healthy) and in neurons from ChAc patients (ChAc). (b) Arithmetic means (±SEM, n = 4) of ORAI1 protein levels in neurons generated from healthy volunteers (white bar) and in neurons from ChAc patients (black bar). (c) Original Western blot of ORAI1 protein abundance in neurons from ChAc patients without (Ø) and with prior lithium (24 h, 2 mM) treatment without (+Li) and with (+Li + GSK) additional presence of SGK1 inhibitor GSK650394 (10 µM). (d) Arithmetic means (±SEM, n = 4) of ORAI1 protein levels in neurons differentiated from ChAc patients without (black bar) or with lithium (24 h, 2 mM) treatment without (light grey bar) and with (dark grey bar) presence of SGK1 inhibitor GSK650394 (10 µM). (e) Original Western blot of STIM1 protein abundance in neurons from ChAc patients without (Ø) and with prior lithium (24 h, 2 mM) treatment without (+Li) and with (+Li + GSK) additional presence of SGK1 inhibitor GSK650394 (10 µM). (f) Arithmetic means (±SEM, n = 3) of STIM1 protein abundance in neurons differentiated from ChAc patients without (black bar) or with lithium (24 h, 2 mM) treatment without (light grey bar) and with (dark grey bar) presence of SGK1 inhibitor GSK650394 (10 µM). ***(p < 0.001) indicates statistically significant difference to respective value in neurons from healthy volunteers, #(p < 0.05), ##(p < 0.01) indicates statistically significant difference to respective value in absence of lithium. §(p < 0.05), §§(p < 0.01) indicates statistically significant difference to respective value in the absence of GSK650394.